Clearbridge Investments LLC Lowers Stock Holdings in argenex SE $ARGX

Clearbridge Investments LLC trimmed its stake in argenex SE (NASDAQ:ARGX) by 32.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 513,764 shares of the company’s stock after selling 243,098 shares during the period. Clearbridge Investments LLC owned about 0.83% of argenex worth $432,050,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. boosted its position in argenex by 2.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock valued at $372,000 after buying an additional 12 shares during the period. Valeo Financial Advisors LLC boosted its position in argenex by 0.9% in the 4th quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock valued at $1,153,000 after buying an additional 12 shares during the period. Sound View Wealth Advisors Group LLC boosted its position in argenex by 3.4% in the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 396 shares of the company’s stock valued at $292,000 after buying an additional 13 shares during the period. Allworth Financial LP boosted its position in argenex by 12.7% in the 4th quarter. Allworth Financial LP now owns 115 shares of the company’s stock valued at $97,000 after buying an additional 13 shares during the period. Finally, Portside Wealth Group LLC boosted its position in argenex by 2.8% in the 3rd quarter. Portside Wealth Group LLC now owns 583 shares of the company’s stock valued at $430,000 after buying an additional 16 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Stock Performance

Shares of ARGX opened at $891.32 on Friday. The company has a 50 day moving average price of $794.90 and a 200-day moving average price of $813.42. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The stock has a market capitalization of $55.43 billion, a PE ratio of 39.68, a PEG ratio of 1.36 and a beta of 0.47.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. The firm had revenue of $1.31 billion during the quarter. Equities research analysts forecast that argenex SE will post 26.25 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on ARGX shares. Wall Street Zen cut shares of argenex from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Royal Bank Of Canada lowered their price target on shares of argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research report on Friday, February 27th. Wedbush reaffirmed an “outperform” rating and issued a $1,000.00 price target on shares of argenex in a research report on Thursday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1,019.50.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.